When comparing P-SMAD3 immunostaining between control and Ahr cKO medulloblastomas, we found that the number of cells with detectable P-SMAD3, as well as the intensity of P-SMAD3 staining in these cells, were increased in Ahr-deficient tumour tissue (Fig. 4d). This evidence concerns the gene AHR and neoplasm.